Cocrystal Pharma commences patient enrollment for Hong Kong phase 2a study of CC-31244
Cocrystal Pharma announced today that it has commenced patient enrollment in its Phase 2a study in Hong Kong SAR, China. The Phase 2a open-label study will evaluate safety, tolerability and preliminary efficacy of CC-31244 in combination with Sofosbuvir and Daclatasvir for treatment of hepatitis C. May 20, 2019